Johnson & Johnson (NYSE:JNJ) stock rose 0.064% (As on July 18, 11:23:54 AM UTC-4, Source: Google Finance) after the company’s second-quarter profit beat Wall Street projections on strong pharmaceutical sales, while the company cut its full-year forecast to account for a spate of recent acquisitions. J&J is counting on its medicines for cancer and autoimmune disease to make up for Stelara’s impending decline. Darzalex, a multiple myeloma treatment that’s now J&J’s biggest drug, beat analysts’ projections in the second quarter, as did the psoriasis treatment Tremfya and prostate cancer medicine Erleada In the Innovative Medicine segment, the company saw worldwide operational sales growth of 8.8%, excluding the COVID-19 Vaccine, driven by strong performance in Oncology and Immunology. The MedTech segment also exhibited growth, with worldwide operational sales up by 4.4%, primarily due to gains in electrophysiology products and wound closure products.
Moreover, DARZALEX growth was 21.3%, primarily driven by share gains of 4.6 points across all lines of therapy and 9.4 points in the frontline setting, as well as market growth. CARVYKTI achieved sales of $186 million with growth of 59.9%, driven by continued capacity expansion, manufacturing efficiencies and strong demand. TECVAYLI sales achieved $135 million in the quarter with growth of 43.5%, reflecting a strong launch in the relapsed refractory setting.
Meanwhile, J&J has proposed settling the majority of the outstanding talc claims by paying out more than $6 billion over 25 years. Plaintiffs have until July 26 to vote in favor of the deal, and J&J needs the support of at least 75% of claimants to move forward. The company is “cautiously optimistic” the settlement will go through.
JNJ in the second quarter of FY 24 has reported the adjusted earnings per share of $2.82, beating the analysts’ estimates for the adjusted earnings per share by 11 cents. The company had reported the adjusted revenue of $22.45 billion in the second quarter of FY 24, beating the analysts’ estimates for revenue of $22.34 billion.
The company said it would generate operational sales of $89.4 billion in 2024, an increase of 6.4% from a year earlier, after its $13.1 billion buyout of the device firm Shockwave Medical. J&J also bought Proteologix Inc. in June and the experimental eczema treatment NM26 from privately held Numab Therapeutics in July.
The adjusted operational earnings for the year is expected to be $10.05 a share, down from the $10.68 a share midpoint estimate it issued in April. The forecast includes a 5 cents per share gain from improved performance.